首页 工具
登录
购物车
Tiplaxtinin

Tiplaxtinin

产品编号 T2030   CAS 393105-53-8
别名: PAI-039, Tiplasinin

Tiplaxtinin (Tiplasinin) 是一种具有口服活性的选择性纤溶酶原激活物抑制剂-1 抑制剂,IC50为 2.7 μM。

TargetMol的所有产品和服务仅用于科学研究,不能被用于人体,我们也不向个人提供产品和服务。
Tiplaxtinin Chemical Structure
Tiplaxtinin, CAS 393105-53-8
规格 价格/CNY 货期 数量
1 mg ¥ 235 现货
2 mg ¥ 333 现货
5 mg ¥ 543 现货
10 mg ¥ 793 现货
25 mg ¥ 1,580 现货
50 mg ¥ 2,970 现货
100 mg ¥ 4,390 现货
500 mg ¥ 9,190 现货
1 mL * 10 mM (in DMSO) ¥ 651 现货
产品目录号及名称: Tiplaxtinin (T2030)
点击图片重新获取验证码
选择批次  
纯度: 99.49%
纯度: 99.26%
纯度: 99.16%
更多批次查询请联系客服
生物活性
化学信息
存储 & 溶解度
参考文献
产品描述 Tiplaxtinin (Tiplasinin)(PAI-039) is a selective and orally efficacious inhibitor of plasminogen activator inhibitor-1 (PAI-1) with IC50 of 2.7 uM.
靶点活性 PAI-1:2.7 μM
体外活性 In a panel of human bladder cell lines, PAI-1 results in the reduction of cellular proliferation, cell adhesion, and colony formation, and the induction of apoptosis and anoikis. [4]
体内活性 In a rat carotid thrombosis model, Tiplaxtinin (1 mg/kg, p.o.) increases time to occlusion and prevents the carotid blood flow reduction. [1] In C57BL/6J mice, (1 mg/g chow) attenuates Ang II-induced aortic remodeling. [2] In untreated type 1 diabetic mice, Tiplaxtinin (p.o.) restores skeletal muscle regeneration. [3] In athymic mice bearing human cancer cell line T24 and HeLa xenografts, Tiplaxtinin (1 mg/kg, p.o.) reduces tumor xenograft growth, associated with a reduction in tumor angiogenesis, a reduction in cellular proliferation, and an increase in apoptosis. [4]
激酶实验 Direct PAI-I in vitro activity assays : The chromogenic assay is initiated by the addition of tiplaxtinin (10 – 100 μM final concentration, maximum DMSO concentration of 0.2%) to recombinant human PAI-1 (140 nM in pH 6.6 buffer). After a 15 minute incubation at 25°C, 70 nM of recombinant human t-PA is added, and the combination of tiplaxtinin, PAI-1 and tPA are incubated for an additional 30 minutes. After the second incubation, Spectrozyme tPA, is added and absorbance read at 405 nm at 0 and 60 minutes. Relative PAI-1 inhibitory activity is equal to the residual tPA activity in the tiplaxtinin / PAI-1 treatment. Control treatments include the complete inhibition of tPA by PAI-1 at the molar ratio employed (2:1), and the absence of any effect of the tiplaxtinin on t-PA alone. The immunofunctional assay is based upon the non-SDS dissociable interaction between tPA and active PAI-1. Assay plates are coated with 100 μl of a solution of t-PA (10 μg/ml in TBS), and kept at 4 °C overnight. Tiplaxtinin is dissolved in DMSO and diluted to a final concentration of 1-100 μM as described above. Tiplaxtinin is then incubated with human PAI-1 (50 ng/ml) for 15 minutes, and an aliquot of this solution added to the t-PA-coated plate for 1 h. The solution is aspirated from the plate, which is then washed with a buffer consisting of 0.05% Tween 20 and 0.1% BSA in TBS. This assay detects only active inhibitory PAI-1 (not latent or substrate) bound to the plate, and is quantitated using a monoclonal antibody against human PAI-1 (MA33B8). A 1000X dilution of MA33B8 is added to the plate and incubated at for one hour, aspirated and washed. A secondary antibody consisting of goat anti-mouse IgG (H+L)-AP alkaline phosphatase conjugate is added, incubated for one hour, aspirated and washed. A 100 μl aliquot of alkaline phosphatase solution is added, followed by determination of absorbance at 405 nm 60 minutes later.The quantitation of residual active PAI-1 bound to t-PA at varying concentrations of tiplaxtinin is used to determine the IC50 by fitting the results to a logistic dose-response program, with the IC50 defined as the concentration of compound required to achieve 50% inhibition of PAI-1 activity. The assay sensitivity is 5 ng/ml of human PAI-1 as determined from a standard curve ranging from 0-100 ng/ml of human PAI-1.
细胞实验 Briefly, cell lines, T24, UM-UC-14, UROtsa, and HeLa cells are plated in 96-well dishes in triplicate at 1×103 cells per well and allowed to adhere for 24 hours. Subsequently, tiplaxtinin is added to the wells and allowed to incubate at the indicated concentrations. Cellular proliferation is determined by CellTiter-Glo Luminescent Cell Viability Assay according to manufacturer's instructions at 24 hours, and IC50 of tiplaxtinin is determined in Graphpad Prism. Luminescence was measured using a FLUOstar OPTIMA Reader.(Only for Reference)
别名 PAI-039, Tiplasinin
分子量 439.38
分子式 C24H16F3NO4
CAS No. 393105-53-8

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度

H2O: < 1 mg/mL (insoluble or slightly soluble)

Ethanol: 15 mg/mL (34.1 mM)

DMSO: 67 mg/mL (152.5 mM)

溶液配制表

可选溶剂 浓度 体积 质量 1 mg 5 mg 10 mg 25 mg
Ethanol / DMSO 1 mM 2.2759 mL 11.3797 mL 22.7593 mL 56.8984 mL
5 mM 0.4552 mL 2.2759 mL 4.5519 mL 11.3797 mL
10 mM 0.2276 mL 1.138 mL 2.2759 mL 5.6898 mL
20 mM 0.1138 mL 0.569 mL 1.138 mL 2.8449 mL
DMSO 50 mM 0.0455 mL 0.2276 mL 0.4552 mL 1.138 mL
100 mM 0.0228 mL 0.1138 mL 0.2276 mL 0.569 mL

计算器

摩尔浓度计算器
稀释计算器
配液计算器
分子量计算器
=
X
X
X
=
X
=
/
g/mol

输入分子式,点击计算,可计算出产品的分子量。

参考文献

1. Elokdah H, et al. J Med Chem. 2004, 47(14), 3491-3494. 2. Weisberg AD, et al. Arterioscler Thromb Vasc Biol. 2005, 25(2), 365-371. 3. Krause MP, et al. Diabetes. 2011, 60(7), 1964-1972. 4. Gomes-Giacoia E, et al. Mol Cancer Ther. 2013, 12(12), 2697-2708.

文献引用

1. Zhang W, Yang S, Chen D, et al. SOX2-OT induced by PAI-1 promotes triple-negative breast cancer cells metastasis by sponging miR-942-5p and activating PI3K/Akt signaling. Cellular and Molecular Life Sciences. 2022, 79(1): 1-16. 2. Chen X, Wang H, Wu C, et al.Endothelial H2S-AMPK dysfunction upregulates the angiocrine factor PAI-1 and contributes to lung fibrosis.Redox Biology.2024: 103038.
ZLDI-8 NSC 146109 hydrochloride Mycophenolic acid Ginsenoside Rk1 Genistein LQZ-7F Acyclovir BMS-536924

相关化合物库

该产品包含在如下化合物库中:
自噬库 表型筛选靶点鉴定库 NO PAINS 化合物库 抗心血管疾病化合物库 活性脂质化合物库 抗代谢疾病化合物库 细胞凋亡化合物库 ReFRAME 相关化合物库 含氟化合物库 抑制剂库

剂量换算

对于不同动物的给药剂量换算,您也可以参考 更多...

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。

第一步:请输入动物实验的基本信息
剂量
mg/kg
每只动物体重
g
给药体积
μL
动物数量
第二步:请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% ddH2O
计算 重置

技术支持

您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。

Keywords

Tiplaxtinin 393105-53-8 Apoptosis Metabolism PAI-1 Inhibitor PAI 039 Plasminogen activator inhibitor-1 PAI-039 inhibit PAI039 Tiplasinin inhibitor

 

陶术
生物
TargetMol®中国区唯一合作伙伴
点击进入陶术生物官网陶术生物
联系我们
400-820-0310

上海市静安区江场三路238号8楼